Clinical trials: Liver Inflammation
Chronic Hepatitis C Infection
Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (what the body does to the medication) and antiviral activity of JNJ-47910382 when administered in different dosing regimens in Caucasian…
- Trial name
- NCT01651767
- Testing
- JNJ-47910382
- Where
- 6 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Janssen R&D Ireland
Chronic Hepatitis B
A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients
Open-label, extension study to evaluate the safety and efficacy of combination therapy and its effect on sustained viral response biomarkers.
- Trial name
- NCT03780543
- Testing
- standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 92 people
- Sponsor
- Assembly Biosciences
Hepatitis C
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
The purpose of this study is to investigate the efficacy of a treatment with TMC435 in combination with peginterferon alfa-2a and ribavirin in patients who did not clear their hepatitis C infection with peginterferon alfa-2a and…
- Trial name
- NCT01323244
- Testing
- TMC435
- Where
- 72 sites in United States, Argentina and 20 more
- Volunteers
- 142 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C, Chronic
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Primary Objective: To determine the P1101 pharmacokinetic (PK) profile at the single dose of 400 μg.
- Trial name
- NCT04774107
- Testing
- P1101 + Ribavirin
- Where
- 5 sites in Taiwan
- Volunteers
- 17 people
- Sponsor
- PharmaEssentia
Chronic Hepatitis B Virus Infection
A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients
This is a randomized, double-blind, placebo-controlled Phase I dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of multiple ascending doses (120 mg, 240 mg, 480 mg SC, QW×5) of…
- Trial name
- NCT07515209
- Testing
- HH-006, 0.9% normal saline
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Huahui Health
Hepatitis C, Chronic
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
This study will evaluate the addition of a higher-dose induction treatment period with peginterferon (PEG-IFN) alfa-2a (Pegasys) and ribavirin prior to standard-dose treatment with PEG-IFN alfa-2a and ribavirin, compared to…
- Trial name
- NCT00192647
- Testing
- PEG-IFN alfa-2a, Ribavirin
- Where
- 51 sites in Argentina, Australia and 4 more
- Volunteers
- 896 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginterferon alfa-2a) and Copegus…
- Trial name
- NCT01220947
- Testing
- Copegus, Danoprevir, Pegasys
- Where
- 68 sites in United States, Austria and 9 more
- Volunteers
- 421 people
- Sponsor
- Hoffmann-La Roche
Acellular Pertussis, Tetanus
Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' Infanrix hexa, given in the primary vaccination schedule to infants born to pregnant women who participated in study 116945 [DTPA…
- Conditions
- Acellular Pertussis, Tetanus, Poliomyelitis, Diphtheria
- Trial name
- NCT02422264
- Testing
- Infanrix hexa, Prevnar13
- Where
- 30 sites in Australia, Canada and 4 more
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis b
Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects
This is a single center, open-label, 3-Cohort, parallel, single-dose, study to evaluate the PK, safety, and tolerability of ATI-2173 50 mg administered orally in Japanese, Chinese, and Non-Asian healthy subjects incorporating a…
- Trial name
- NCT05298332
- Testing
- ATI-2173 50 mg
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Antios Therapeutics, Inc
HIV Infections, Hepatitis C
Multicenter Performance Study of QuadQuik Invitro Diagnostic Device
To Demonstrate Clinical Performance of the TriQuik Invitro Diagnostic Device
- Conditions
- HIV Infections, Hepatitis C, Hepatitis B, Syphilis Infection
- Trial name
- NCT05692505
- Testing
- QuadQuik
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Genlantis Diagnostics
Hepatitis B
Phase Ia/Ib Trial of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B
Study SCTA02A-A101 is designed to assess the safety, tolerability and pharmacokinetics of SCTA02A in healthy volunteers and participants with chronic hepatitis B virus infection.
- Trial name
- NCT07903831
- Testing
- SCTA02A
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Hepatitis B Virus Infection
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
- Trial name
- NCT07024641
- Testing
- GIGA-2339
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 48 people
- Sponsor
- GigaGen, Inc.
Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)
Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide
The proposed indication for Hydronidone Capsules is chronic hepatitis B-associated liver fibrosis, which in clinical practice typically requires concomitant use with antiviral agents for chronic hepatitis B.
- Trial name
- NCT07295873
- Testing
- Entecavir, Tenofovir Disoproxil Fumarate（TDF）, Tenofovir alafenamide（TAF）
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hepatitis C
Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects
The primary purpose of this study is to assess the effect of the Daclatasvir/Asunaprevir/BMS-791325 fixed dose combination (FDC) tablet on the pharmacokinetics of the cocktail CYP and transporter probe substrates and to assess…
- Trial name
- NCT02045966
- Testing
- Cocktail, DCV 3DAA FDC, BMS-791325
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Alcoholic Hepatitis, Acute Alcoholic Hepatitis
MRG-001 in Patients With Alcoholic Hepatitis
The goal of this study is to test MRG-001 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of MRG-001 in patients with severe alcoholic hepatitis…
- Trial name
- NCT06307522
- Testing
- MRG-001
- Volunteers
- 32 people
- Sponsor
- MedRegen LLC
Hepatitis C, Chronic
A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
This open-label, parallel cohort study will evaluate the safety, pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve…
- Trial name
- NCT01483742
- Testing
- RO5024048, danoprevir, peginterferon alfa-2a [Pegasys]
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies
The primary objective of this study is to assess changes in alanine aminotransferase (ALT) in hepatitis C virus (HCV)-infected subjects given daily doses of JKB-122 for 3 months who have been nonresponsive to, intolerable to, or…
- Trial name
- JKB122 (NCT02293941)
- Testing
- JKB-122 5mg, JKB-122 15mg, JKB-122 35mg
- Where
- 14 sites in Taiwan
- Volunteers
- 54 people
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Hepatitis
A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers
A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers.
- Trial name
- NCT02920931
- Testing
- Tenofovir disoproxil
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hepatitis C
An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
To assess efficacy of telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) for hepatitis C virus (HCV) in a 48-week total treatment duration regimen following liver transplantation.
- Trial name
- NCT01467505
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
- Where
- 22 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)
This retrospective study will assess the sustained virologic response and the safety of two different interferons (pegylated or conventional) in patients with chronic hepatitis C. Data will be collected for 24 weeks.
- Trial name
- NCT01280656
- Testing
- Conventional Interferon, Peginterferon Alfa-2a, Peginterferon Alfa-2b
- Where
- 37 sites in Brazil
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.